P-glycoprotein function at the blood-brain barrier: Effects of age and gender

Molecular Imaging and Biology

Volumn 14, Issue 6, 2012, Pages 771-776

  Van Assema, Daniëlle M E ^a,b   Lubberink, Mark ^a,c   Boellaard, Ronald ^a   Schuit, Robert C ^a   Windhorst, Albert D ^a   Scheltens, Philip ^b   Lammertsma, Adriaan A ^a   Van Berckel, Bart N M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

(R) 11C verapamil; Aging; Blood brain barrier; Gender; P glycoprotein; Positron emission tomography

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGE; AGED; AGING; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; FEMALE; GRAY MATTER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE;

ADULT; AGED; AGING; BLOOD-BRAIN BARRIER; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; REGRESSION ANALYSIS; SEX CHARACTERISTICS; VERAPAMIL; YOUNG ADULT;

EID: 84870465393     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0556-0     Document Type: Article

References (38)

1. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201
2. Neuwelt E, Abbott NJ, Abrey L et al (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7:84-96
3. Loscher W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76
4. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429
5. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-194
6. Loscher W, Potschka H (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98
7. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403
8. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373:2055-2066
9. Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a metaanalysis. Arch Gen Psychiatry 55:809-815
10. Launer LJ, Andersen K, Dewey ME et al (1999) Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 52:78-84
11. Candore G, Balistreri CR, Grimaldi MP et al (2006) Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease. Ann N Y Acad Sci 1089:472-486
12. Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018
13. Bebawy M, Chetty M (2009) Gender differences in P-glycoprotein expression and function: effects on drug disposition and outcome. Curr Drug Metab 10:322-328
14. Hendrikse NH, de Vries EG, Eriks-Fluks L et al (1999) A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 59:2411-2416
15. Hendrikse NH, Bart J, de Vries EG, Groen HJ, van der Graaf WT, Vaalburg W (2001) P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J Clin Pharmacol Suppl:48S-54S
16. Lubberink M, Luurtsema G, van Berckel BN et al (2007) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 27:424-433
17. Toornvliet R, van Berckel BN, Luurtsema G et al (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540-548
18. Bartels AL, Kortekaas R, Bart J et al (2009) Blood-brain barrier Pglycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 30:1818-1824
19. Bauer M, Karch R, Neumann F et al (2009) Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol 65:941-946
20. van Assema DM, Lubberink M, Bauer M et al (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135:181-189
21. Bartels AL, Willemsen AT, Kortekaas R et al (2008) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease. PSP and MSA. J Neural Trans 115:1001-1009
22. Bartels AL, van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL (2008) Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Related Disord 14:505-508
23. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
24. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26:449-462
25. Didziapetris R, Japertas P, Avdeef A, Petrauskas A (2003) Classification analysis of P-glycoprotein substrate specificity. J Drug Target 11:391-406
26. Brix G, Zaers J, Adam LE et al (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38:1614-1623
27. Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA (2001) Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 28:81-89
28. Mourik JE, Lubberink M, Klumpers UM, Comans EF, Lammertsma AA, Boellaard R (2008) Partial volume corrected image derived input functions for dynamic PET brain studies: methodology and validation for [11C]flumazenil. NeuroImage 39:1041-1050
29. Brix G, Doll J, Bellemann ME et al (1997) Use of scanner characteristics in iterative image reconstruction for high-resolution positron emission tomography studies of small animals. Eur J Nucl Med 24:779-786
30. Mourik JE, Lubberink M, van Velden FH et al (2010) in vivo validation of reconstruction-based resolution recovery for human brain studies. J Cereb Blood Flow Metab 30:381-389
31. Svarer C, Madsen K, Hasselbalch SG et al (2005) MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage 24:969-979
32. Gunn RN, Sargent PA, Bench CJ et al (1998) Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. NeuroImage 8:426-440
33. Luurtsema G, Molthoff CF, Windhorst AD et al (2003) (R)-and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 30:747-751
34. Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M (2004) Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L-and D-verapamil examined with a stable isotope technique. 1984. Br J Clin Pharmacol 58:S796-S803
35. Muzi M, Mankoff DA, Link JM et al (2009) Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 50:1267-1275
36. Wagner CC, Bauer M, Karch R et al (2009) A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 50:1954-1961
37. van Assema DM, Lubberink M, Boellaard R et al (2012) Reproducibility of quantitative (R)-[11C]verapamil studies. EJNMMI Res 2:1
38. Dagenais C, Zong J, Ducharme J, Pollack GM (2001) Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res 18:957-963